Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
NKTR Quote, Financials, Valuation and Earnings
Last price:
$43.88
Seasonality move
:
7.44%
Day range:
$43.16 - $44.25
52-week range:
$6.48 - $66.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
45.31x
P/B ratio:
8.93x
Volume:
300.3K
Avg. volume:
864.8K
1-year change:
222.69%
Market cap:
$760.2M
Revenue:
$98.4M
EPS (TTM):
-$4.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$10.2M | -$2.79 | -64.24% | -1474.64% | $114.43 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
APYX
Apyx Medical Corp.
|
$12M | -$0.10 | 22.81% | -50.45% | $6.00 |
|
OWLT
Owlet, Inc.
|
$26.8M | -$0.20 | 26% | -81.11% | $14.88 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$61.9M | $0.94 | 15.36% | 30.92% | $51.20 |
|
ZVRA
Zevra Therapeutics, Inc.
|
$26.6M | -$0.02 | 132.94% | -99.63% | $22.54 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$43.94 | $114.43 | $760.2M | -- | $0.00 | 0% | 45.31x |
|
AMGN
Amgen, Inc.
|
$333.89 | $325.88 | $179.8B | 25.81x | $2.38 | 2.85% | 5.04x |
|
APYX
Apyx Medical Corp.
|
$3.65 | $6.00 | $139.6M | -- | $0.00 | 0% | 3.06x |
|
OWLT
Owlet, Inc.
|
$15.27 | $14.88 | $421.2M | -- | $0.00 | 0% | 2.56x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$44.64 | $51.20 | $810.3M | 7.24x | $0.00 | 0% | 2.91x |
|
ZVRA
Zevra Therapeutics, Inc.
|
$8.64 | $22.54 | $486.4M | 13.70x | $0.00 | 0% | 5.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
APYX
Apyx Medical Corp.
|
87.02% | 4.234 | 48.31% | 3.58x |
|
OWLT
Owlet, Inc.
|
-182.74% | 3.918 | 16.06% | 0.85x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 2.066 | 11.84% | 1.94x |
|
ZVRA
Zevra Therapeutics, Inc.
|
32.02% | 1.762 | 11.73% | 8.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
APYX
Apyx Medical Corp.
|
$5.1M | -$832K | -29.7% | -146.08% | -6.46% | -$4.1M |
|
OWLT
Owlet, Inc.
|
$16.2M | $1.2M | -- | -- | 3.8% | -$2.6M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
|
ZVRA
Zevra Therapeutics, Inc.
|
$24.5M | $4.1M | 24.95% | 44.06% | 15.9% | $4.2M |
Nektar Therapeutics vs. Competitors
-
Which has Higher Returns NKTR or AMGN?
Amgen, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 33.55%. Nektar Therapeutics's return on equity of -327.67% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About NKTR or AMGN?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 160.42%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -1.69%. Given that Nektar Therapeutics has higher upside potential than Amgen, Inc., analysts believe Nektar Therapeutics is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 AMGNAmgen, Inc.10 15 2 -
Is NKTR or AMGN More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock NKTR or AMGN?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $2.38 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or AMGN?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Nektar Therapeutics's net income of -$35.5M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 25.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.31x versus 5.04x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M AMGNAmgen, Inc.5.04x 25.81x $9.6B $3.2B
-
Which has Higher Returns NKTR or APYX?
Apyx Medical Corp. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -15.18%. Nektar Therapeutics's return on equity of -327.67% beat Apyx Medical Corp.'s return on equity of -146.08%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M APYXApyx Medical Corp.39.65% -$0.05 $45.3M -
What do Analysts Say About NKTR or APYX?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 160.42%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 66.67%. Given that Nektar Therapeutics has higher upside potential than Apyx Medical Corp., analysts believe Nektar Therapeutics is more attractive than Apyx Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 APYXApyx Medical Corp.3 1 0 -
Is NKTR or APYX More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.486, suggesting its more volatile than the S&P 500 by 48.62%.
-
Which is a Better Dividend Stock NKTR or APYX?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or APYX?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Apyx Medical Corp. quarterly revenues of $12.9M. Nektar Therapeutics's net income of -$35.5M is lower than Apyx Medical Corp.'s net income of -$2M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.31x versus 3.06x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M APYXApyx Medical Corp.3.06x -- $12.9M -$2M
-
Which has Higher Returns NKTR or OWLT?
Owlet, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 12.58%. Nektar Therapeutics's return on equity of -327.67% beat Owlet, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M OWLTOwlet, Inc.50.51% $0.13 -$13.7M -
What do Analysts Say About NKTR or OWLT?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 160.42%. On the other hand Owlet, Inc. has an analysts' consensus of $14.88 which suggests that it could fall by -2.59%. Given that Nektar Therapeutics has higher upside potential than Owlet, Inc., analysts believe Nektar Therapeutics is more attractive than Owlet, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 OWLTOwlet, Inc.5 0 0 -
Is NKTR or OWLT More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.734, suggesting its more volatile than the S&P 500 by 73.364%.
-
Which is a Better Dividend Stock NKTR or OWLT?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or OWLT?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Nektar Therapeutics's net income of -$35.5M is lower than Owlet, Inc.'s net income of $4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.31x versus 2.56x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M OWLTOwlet, Inc.2.56x -- $32M $4M
-
Which has Higher Returns NKTR or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 40.17%. Nektar Therapeutics's return on equity of -327.67% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M -
What do Analysts Say About NKTR or RIGL?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 160.42%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 14.7%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is NKTR or RIGL More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.
-
Which is a Better Dividend Stock NKTR or RIGL?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or RIGL?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Nektar Therapeutics's net income of -$35.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 7.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.31x versus 2.91x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M RIGLRigel Pharmaceuticals, Inc.2.91x 7.24x $69.5M $27.9M
-
Which has Higher Returns NKTR or ZVRA?
Zevra Therapeutics, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -2.09%. Nektar Therapeutics's return on equity of -327.67% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M -
What do Analysts Say About NKTR or ZVRA?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 160.42%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 160.92%. Given that Zevra Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Zevra Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 ZVRAZevra Therapeutics, Inc.6 0 0 -
Is NKTR or ZVRA More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.92699999999999%.
-
Which is a Better Dividend Stock NKTR or ZVRA?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or ZVRA?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. Nektar Therapeutics's net income of -$35.5M is lower than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Zevra Therapeutics, Inc.'s PE ratio is 13.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.31x versus 5.59x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
